Pharmaceuticals

Global Gastric Cancer Drugs Market Set for Strong Expansion, Reaching $8.14 Billion With 10.9% CAGR by 2030

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastric cancer drugs market from 2026–2035 with trusted insights from The Business Research Company

How much is the Gastric Cancer Drugs Market valued at in 2026, and what valuation is forecast for 2030?

The gastric cancer drugs market has shown strong expansion in recent years. It is projected to increase from $4.9 billion in 2025 to $5.39 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.9%. The growth witnessed historically can be linked to the increasing prevalence of gastric cancer, limited early detection awareness, continued reliance on conventional chemotherapy, the rising adoption of hospital-based treatment, and the high cost of branded drugs.

The gastric cancer drugs market is projected for swift expansion in the coming years. This market is anticipated to reach $8.14 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.9%. Its growth during the forecast period is fueled by progress in targeted therapies, a rise in immunotherapy adoption, the broader application of precision medicine, the creation of new oral and injectable formulations, and increased governmental and private investment in cancer research. Key trends foreseen include individualized gastric cancer treatments, the emergence of targeted drug delivery systems, a greater reliance on combination therapies, the expansion of services for outpatient cancer treatment, and an increase in supportive care alongside symptom management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Drivers Are Influencing The Growth Of The Gastric Cancer Drugs Market?

The global rise in the aging population is projected to fuel the expansion of the gastric cancer drug market in the coming years. An aging population describes a demographic scenario where a substantial portion of a country’s or area’s inhabitants are older, generally 65 years or older. This trend emerges from a continuous rise in life expectancy combined with declining birth rates, leading to a greater share of older people within the total population. Elderly patients might have reduced tolerance for specific cancer therapies, including surgery or chemotherapy. Consequently, a demand arises for more customized treatment approaches, such as pharmaceuticals, to meet the unique requirements and sensitivities of older individuals. For example, data from July 2024, provided by the UK Parliament’s House of Commons Library, a UK-based government body, indicated that in 2022, the UK had 12.7 million individuals aged 65 or above, constituting 19% of its entire population. This figure is expected to increase to 22.1 million by 2072, making up 27% of the population. Hence, the gastric cancer drug market is forecasted to expand going forward, propelled by the expanding elderly demographic.

How Is The Gastric Cancer Drugs Market Organized Into Various Segments?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Which Innovation Trends Are Advancing Developments Within The Gastric Cancer Drugs Market?

Companies within the gastric cancer drugs market are channeling their efforts into developing innovative products, such as CLDN18.2-targeted treatments, with the aim of enhancing the effectiveness of therapies and providing more personalized options for patients. CLDN18.2-targeted treatment refers to therapeutic approaches specifically engineered to target claudin 18.2 (CLDN18.2), a protein predominantly found in certain epithelial tissues, including the gastric epithelium. For example, in October 2024, Astellas Pharma Inc., a Japan-based company, secured approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting the public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) stands as the initial CLDN18.2-targeted treatment indicated for advanced gastric and gastroesophageal junction cancer where tumors are CLDN18.2 positive. This treatment is administered alongside fluoropyrimidine- and platinum-based chemotherapy regimens. Its use is specified for adults diagnosed with locally advanced unresectable negative gastric or gastroesophageal junction cancer adenocarcinoma.

Who Are The Core Companies Influencing Trends In The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Regions Are Projected To Dominate The Gastric Cancer Drugs Market In The Coming Years?

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastric Cancer Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795